human
adenoviru
hadv
common
caus
infect
ocular
surfac
account
conjunct
common
present
pharyngoconjunctiv
fever
pcf
often
occur
children
manifest
clinic
fever
pharyng
rhiniti
follicular
conjunct
region
lymphoid
epidem
keratoconjunct
ekc
sever
ocular
form
distinguish
abil
invad
corneal
epithelium
rang
present
kerat
persist
recurr
subepitheli
infiltr
sei
hadv
highli
contagi
due
uniqu
structur
abil
evad
normal
host
immun
system
distinguish
type
conjunct
often
involv
cornea
potenti
devast
visual
complic
featur
contribut
heavi
econom
burden
necessit
establish
standard
treatment
addit
potenti
ocular
manifest
viru
hadv
infect
propens
manifest
system
case
respiratori
urinari
gastrointestin
tract
git
infect
varieti
present
infect
normal
healthi
host
also
increas
risk
immunocompromis
individu
despit
detriment
effect
hadv
infect
pose
yet
fdaapprov
drug
treat
condit
make
manag
difficult
even
follow
activ
phase
diseas
viral
persist
reactiv
may
occur
oral
topic
antivir
consid
offlabel
manag
solut
problem
efficaci
bioavail
therapeut
profil
limit
use
regard
ekc
topic
disinfect
activ
case
well
treatment
corneal
sequela
use
corticosteroid
immunosuppress
agent
show
promis
review
focu
persist
dissemin
hadv
pose
signific
challeng
manag
adenovir
keratoconjunct
furthermor
current
futur
trend
prophylact
therapeut
modal
adenovir
keratoconjunct
discuss
hadv
belong
genu
mastadenoviru
famili
adenovirida
nonenvelop
viru
linear
dsdna
genom
icosahedr
capsid
hadv
consist
group
classifi
genom
sequenc
adenoviralbas
ocular
surfac
infect
attribut
sever
subtyp
group
b
hadv
gener
virus
bind
ubiquit
express
transmembran
protein
infect
exposur
host
hadv
made
possibl
interact
adenovir
fiber
protein
primari
host
cellular
receptor
sialic
acid
heparinsulf
proteoglycan
promot
attach
intern
interact
penton
base
viru
vitronectinbind
integrin
host
support
intern
acidif
endosom
trigger
conform
chang
viral
capsid
process
culmin
releas
viral
dna
genom
host
nucleu
viral
replic
hadv
caus
lytic
infect
mucoepitheli
cell
conjunctiva
cornea
well
latent
infect
lymphoid
adenoid
member
group
b
hadv
caus
git
ocular
infect
see
tabl
subtyp
group
b
hadv
type
group
b
caus
keratoconjunct
urinari
tract
infect
respiratori
infect
git
infect
group
hadv
also
caus
ocular
git
infect
group
b
hadv
subtyp
infect
respiratori
tract
group
b
hadv
includ
type
associ
acut
respiratori
distress
ard
hadv
type
caus
ard
transmit
aerosol
droplet
import
note
respiratori
droplet
fecalor
transmiss
rout
individu
acut
adenovir
infect
even
postinfect
adenovir
shed
play
import
role
transmiss
dynam
hadv
persist
hadv
secret
tear
may
also
occur
even
year
follow
resolut
acut
ocular
infect
cell
tonsillar
adenoid
lymphoid
tissu
serv
reservoir
harbor
hadv
make
possibl
develop
latent
adenovir
reactiv
persist
latent
adenoviru
host
like
facilit
blockad
type
ii
interferon
ifn
respons
requir
inhibit
express
hadv
immunosuppress
steroid
therapi
suppress
product
cytokin
includ
tnfalpha
type
ifn
type
ii
ifn
well
deplet
cell
nk
inadvert
reduc
secret
antivir
cytokin
play
major
role
inhibit
viral
replic
inhibit
ifn
respons
allow
express
hadv
gene
result
reactiv
replic
hadv
dna
epitheli
cell
associ
latent
infect
lymphoid
tissu
consequenti
dissemin
thu
immunosuppress
could
facilit
dissemin
adenoviru
commun
sinc
subclin
adenovir
infect
tonsillar
adenoid
lymphoid
tissu
serv
sourc
transmit
adenovirus
particularli
immunocompromis
children
prior
exposur
immun
particular
strain
addit
asymptomat
passag
adenoviru
stool
patient
previou
adenovir
git
infect
also
kosulin
et
al
suggest
latent
hadv
infect
gut
lymphoid
cell
could
serv
sourc
releas
hadv
particl
garnett
et
al
demonstr
asymptomat
persist
group
c
adenoviru
human
mucos
lymphocyt
lymphoid
tissu
follow
primari
adenovir
stimul
adenoviru
contain
mucos
tlymphocyt
result
reactiv
latent
hadv
consequenti
leakag
reactiv
virus
intestin
epitheli
cell
adenovirus
undergo
replic
subsequ
shed
indic
persist
subclin
hadv
infect
gutassoci
lymphoid
immunocompet
individu
like
shed
less
hadv
stool
contrast
immunocompromis
signific
amount
hadv
releas
immunocompromis
individu
also
like
reactiv
hadv
product
infect
intestin
epitheli
cell
consequenti
extens
viral
dissemin
commun
immunocompromis
state
reactiv
persist
latent
hadv
essenti
caus
hadv
result
latent
adenovir
infect
consid
signific
challeng
manag
contain
viru
within
commun
due
persist
adenovir
shed
high
propens
spread
via
handtoey
contact
contamin
fecal
anoth
signific
challeng
manag
adenovir
infect
particularli
group
hadv
propens
group
caus
oculogenit
infect
sever
publish
case
demonstr
group
hadv
associ
concurr
urethr
hadv
specif
sequest
genit
tract
young
adult
ekc
indic
possibl
sexual
group
hadv
type
exampl
isol
sexual
activ
men
adenovir
addit
liddl
et
al
discuss
eight
case
individu
present
concurr
conjunct
adenovir
avolio
et
al
also
present
case
two
male
patient
hadv
associ
urethr
conjunct
one
spous
contract
adenovir
conjunct
via
oculogenit
contact
case
highlight
import
test
presenc
adenoviru
clinic
specimen
collect
urethr
conjunctiv
swab
men
present
conjunct
dysuria
scant
urethr
though
molecular
iodin
long
establish
effect
antisept
agent
formid
toxic
upon
contact
mucos
surfac
deter
use
clinic
clinic
howev
combin
iodin
povidon
allow
antisept
safe
routin
use
ophthalm
set
even
shown
promis
manag
ekc
affect
individu
povidoneiodin
pvi
broadspectrum
microbicid
solut
exist
multipl
form
easili
access
costeffect
disinfect
agent
sinc
discoveri
routin
util
medic
field
antisept
agent
laboratori
surgic
purpos
furthermor
found
much
purpos
ophthalm
set
effect
disinfect
solut
due
proven
toxic
virus
bacteria
parasit
fungi
yeast
mold
dilut
form
pvi
commerci
sold
betadin
alcon
laboratori
inc
fort
worth
tx
concentr
weaken
medic
use
requir
critic
note
unlik
antisept
pvi
lose
antimicrobi
activ
decreas
avail
iodin
concentr
solut
diluent
mode
action
requir
oxid
pathogen
nucleotid
amino
acid
protein
damag
vital
bacteri
cellular
addit
vitro
investig
indic
pvi
imped
host
inflammatori
respons
viral
pathogen
affect
host
pathogen
may
give
insight
inoffic
pvi
irrig
may
allevi
inflammatori
symptom
associ
ekc
specif
pathogen
consequ
includ
inhibit
product
releas
exotoxin
phospholipas
c
lipas
suppress
bacteri
enzym
elastas
host
factor
involv
modul
antioxid
free
radic
activ
inhibit
inflammatori
effector
cell
mediat
inhibit
matrix
metalloproteinas
product
enhanc
heal
signal
via
activ
cell
global
pvi
characterist
make
ideal
clinic
use
includ
broad
antimicrobi
spectrum
lack
resist
abil
penetr
biofilm
low
cytotox
suitabl
toler
overal
favor
riskbenefit
versatil
eas
access
ubiquit
use
antisepsi
promot
biochem
characterist
compound
combin
synthet
carrier
homopolym
innat
germicid
abil
iodin
form
aqueou
form
free
iodin
releas
solut
pvi
complex
provid
microbicid
studi
shown
pvi
exhibit
antimicrobi
activ
proport
concentr
free
iodin
releas
given
solut
specifi
dilut
regardless
pvi
addit
welldocu
antimicrobi
activ
studi
examin
virucid
efficaci
pvi
demonstr
solut
actual
effect
hadv
maxim
free
iodin
specif
pvi
formul
proven
effect
nonenvelop
human
virus
includ
hadv
although
postul
adenovir
type
pvi
shown
demonstr
virucid
reduct
ocular
hadv
type
min
type
min
variou
may
indic
time
exposur
concentr
pvi
disinfect
critic
virucid
activ
pvi
differ
concentr
may
requir
tempor
consider
evalu
specif
viru
type
though
pvi
test
vitro
anim
model
clinic
use
disinfect
wound
heal
mani
decad
use
pvi
irrig
inoffic
ekc
remain
theori
behind
inoffic
pvi
irrig
reduc
viral
load
ocular
surfac
decreas
viral
shed
commonli
implement
protocol
clinic
practic
involv
anesthet
affect
eye
instil
preirrig
nsaid
drop
follow
four
five
drop
pvi
solut
patient
roll
close
eye
maxim
exposur
includ
swab
eyelid
margin
follow
lavag
ocular
surfac
steril
salin
irrig
solut
figur
final
postirrig
nsaid
drop
instil
anecdot
patient
may
report
exasper
conjunct
symptom
hr
procedur
howev
overal
riskbenefit
consider
regularli
tip
decis
favor
preform
pvi
interestingli
cheung
et
al
indic
multipl
type
adenoviru
involv
singl
outbreak
pvi
proven
viricid
activ
multipl
ocular
type
hadv
would
sensibl
consid
pvi
irrig
decreas
colon
ocular
surfac
diseas
power
tool
limit
sever
adenovir
conjunct
outbreak
includ
reduct
viral
shed
limit
contamin
object
workspac
surfac
public
place
avoid
horizont
transmiss
mention
previous
gargl
flush
pvi
postul
effect
measur
disrupt
transmiss
respiratori
viral
henc
pvi
irrig
power
tool
help
reduct
transmiss
adenovir
keratoconjunct
pvi
also
shown
valu
treatment
formul
larg
clinic
trial
use
pvi
ophthalm
solut
treatment
pediatr
conjunct
display
efficaci
treatment
bacteri
chlamydi
viral
interestingli
clinic
trial
look
pvi
combin
artifici
tear
ph
enhanc
toler
treatment
adenovir
keratoconjunct
found
faster
recoveri
diseas
two
week
three
drop
administ
thrice
antivir
activ
system
hadv
infect
thoroughli
studi
pave
way
focus
evalu
treatment
ocular
manifest
viru
besid
aforement
form
keratoconjunct
hadv
may
also
caus
upper
lower
respiratori
tract
diseas
hemorrhag
cystiti
gastroenter
due
propens
infect
mucos
respiratori
infect
typic
mild
selflimit
immunocompet
individu
rare
case
sever
respiratori
infect
pneumonia
may
result
acut
respiratori
distress
syndrom
ard
addit
immunocompromis
patient
undergo
hematopoiet
stem
cell
solid
organ
transplant
dissemin
infect
lifethreaten
particularli
pediatr
despit
thorough
investig
role
antivir
treatment
system
topic
remain
standard
care
possibl
therapeut
benefit
demonstr
use
antivir
drug
ganciclovir
ribavirin
ganciclovir
gcv
synthet
nucleosid
analog
proven
effect
inhibit
herp
famili
virus
specif
herp
simplex
type
varicellazost
viru
cytomegaloviru
epsteinbarr
seri
experi
util
syrian
immunocompromis
hamster
infect
hadv
gcv
abl
suppress
viral
replic
liver
method
may
involv
direct
inhibit
dna
polymeras
propos
gcv
inhibit
advanc
viral
infect
late
phase
system
gcv
abl
mitig
effect
hadv
infect
hamster
decreas
rate
mortal
led
investig
gcv
treatment
ocular
infect
ophthalm
gel
form
ganciclovir
farmilathea
milan
itali
standard
care
treatment
acut
ocular
herpet
kerat
yet
standard
manag
adenovir
keratoconjunct
particularli
sinc
studi
human
subject
current
research
suggest
howev
offlabel
topic
use
gcv
inhibit
replic
hadv
lead
ocular
infect
sever
clinic
trial
report
one
studi
huang
et
al
investig
antivir
activ
gcv
hadv
type
use
polymeras
chain
reaction
pcr
conclud
signific
dosedepend
inhibitori
effect
serotyp
respons
system
bruno
et
al
describ
potenti
therapeut
effect
gcv
incid
hadv
infect
significantli
reduc
stem
celltranspl
patient
treat
gcv
human
cytomegaloviru
sun
et
al
conduct
studi
util
seri
eye
drop
treat
activ
ekc
infect
includ
gcv
ophthalm
gel
interferon
eye
drop
tobramycindexamethason
combo
topic
diclofenac
sodium
studi
interferon
administ
purpos
inhibit
viral
replic
gcv
use
antivir
properti
improv
efficaci
limit
potenti
ocular
side
effect
inflamm
congest
edema
tobramycindexamethason
diclofenac
sodium
treatment
also
employ
combin
drug
demonstr
cure
rate
treatment
period
low
risk
side
effect
limit
transient
corneal
epitheli
defect
elev
intraocular
pressur
ekc
often
consid
selflimit
studi
conclud
propos
treatment
plan
specif
earli
phase
diseas
could
markedli
reduc
patient
symptom
shorten
cours
diseas
lessen
risk
corneal
valganciclovir
prodrug
gcv
inhibit
replic
adenovir
genom
dna
via
blockad
hadv
dna
polymeras
howev
hadv
lack
thymidin
kinas
known
target
valganciclovir
would
like
becom
challeng
treatment
adenovir
ribavirin
cidofovir
also
shown
exhibit
antivir
activ
hadv
vitro
howev
mani
system
antivir
therapi
lead
risk
signific
side
effect
cidofovir
cdv
acycl
nucleosid
phosphon
nucleotid
analog
cytosin
convert
cell
diphosph
form
bind
hadv
dna
polymeras
caus
viral
dna
chain
termin
viral
intraven
cidofovir
often
use
transplant
clinic
mild
efficaci
due
poor
cellular
uptak
phosphat
group
lead
accumul
drug
renal
tubul
use
system
lead
local
cdv
may
also
caus
ocular
toxic
around
skin
eyelid
similarli
ribavirin
also
result
poor
system
side
effect
safeti
profil
associ
extravascular
hemolysi
anemia
bone
marrow
suppress
due
discoveri
necessari
determin
effect
antivir
high
therapeut
index
treatment
hadv
associ
anim
model
cdv
administ
util
topic
intrastrom
inocul
three
time
per
day
consecut
day
result
display
signific
effect
hadv
type
compar
placebo
group
reduc
viral
shed
sever
subepitheli
infiltr
studi
show
great
promis
futur
cidofovir
treatment
ocular
hadv
infect
addit
earli
system
administr
cdv
immunocompet
patient
hadv
pneumonia
effect
treatment
due
posit
result
aforement
studi
cdv
test
prophylact
measur
due
epidem
natur
hadv
romanowski
et
al
determin
antivir
prophylaxi
concentr
cdv
significantli
reduc
viral
replic
hadv
type
anim
model
give
promis
use
cdv
despit
favor
outcom
cidofovir
antivir
activ
rabbit
model
sever
studi
discuss
signific
side
effect
ocular
surfac
potenti
limit
therapeut
use
gordon
et
al
describ
effect
topic
cidofovir
uninfect
anim
determin
consist
clinic
signific
ocular
toxic
total
dose
exceed
signific
eyelid
red
conjunctiv
hyperemia
also
describ
addit
studi
well
nasolacrim
blockag
even
lower
presum
ineffect
dosag
mg
cidofovir
continu
exhibit
signific
ocular
surfac
toxic
resist
cdv
like
due
chang
amino
acid
sequenc
within
encod
dna
polymeras
gene
resist
hadv
suggest
confer
resist
adenoviru
cdv
drug
resist
pose
signific
challeng
manag
adenovir
keratoconjunct
clinic
romanowski
et
al
abl
demonstr
hadv
type
resist
topic
cvd
therapi
less
like
constitut
signific
challeng
manag
adenovir
keratoconjunct
immunocompet
patient
drugresist
virus
usual
pose
minim
threat
immunocompet
patient
cdvresist
hadv
retain
abil
replic
permiss
ocular
epitheli
anoth
major
challeng
use
cdv
treat
adenovir
keratoconjunct
propens
lead
toxic
manifest
persist
epiphora
lacrim
canalicular
despit
potenti
high
toxic
profil
poor
bioavail
make
cdv
less
ideal
treatment
option
treatment
hadv
associ
infect
system
local
solut
challeng
led
investig
brincidofovir
bcv
lipidlink
deriv
cdv
allow
cell
uptak
drug
readili
administ
follow
cellular
uptak
lipid
compon
cleav
phospholipas
leav
cdv
allow
similar
antivir
efficaci
seen
cdv
without
subsequ
nephrotox
averbuch
et
al
report
success
use
bcv
treatment
adenovir
infect
patient
primari
immunodefici
wherea
florescu
et
al
demonstr
clinic
benefici
treat
adenovir
infect
immunocompromis
individu
risk
dissemin
hadv
suggest
bcv
could
potenti
antiadenovir
therapeut
though
drug
show
promis
still
need
conclus
research
regard
effect
safeti
profil
bcv
system
well
potenti
treatment
adenovir
ocular
infect
clinic
develop
drug
ongo
yet
ophthalm
antivir
comparison
made
ganciclovir
appear
favor
term
antivir
activ
limit
system
local
side
goosen
et
al
discuss
antivir
activ
antiad
igg
gene
transfer
synovi
fluid
attribut
antibodi
abil
target
adenovir
capsid
protein
subsequ
inhibit
infect
topic
immunoglobulin
ig
may
offer
effect
ocular
tissu
prevent
transmiss
replic
viru
degre
addit
antivir
properti
ig
ad
benefit
antiinflammatori
effect
aid
subepitheli
infiltr
nwanegbo
et
al
found
ig
actual
compar
cidofovir
antivir
activ
cidofovir
act
intracellularli
block
dna
replic
ig
neutral
viru
ocular
surfac
comparison
cidofovir
salin
titer
ig
effect
acut
phase
work
aid
clearanc
viru
shorten
durat
infect
therebi
limit
transmiss
viru
addit
ig
may
benefici
prophylaxi
prevent
clinic
infect
though
cidofovir
ig
effect
studi
cidofovir
demonstr
significantli
shorter
durat
viral
shed
like
due
mechan
intracellularmedi
adenovir
dna
polymeraseblock
activ
prolong
tissu
halflif
rapid
uptak
cell
studi
yield
promis
result
futur
topic
ig
use
ocular
hadv
infect
limit
lie
product
consist
ig
deriv
serum
pool
variou
donor
though
antiadenovir
efficaci
appear
stabl
differ
corneal
involv
ekc
occur
approxim
case
vari
present
superfici
punctat
kerat
focal
epitheli
punctat
kerat
subepitheli
infiltr
sei
format
reduc
corneal
sei
specif
often
manifest
anywher
one
three
week
follow
acut
phase
infect
histolog
compris
residu
antigen
lymphocyt
accumul
adher
stromal
cell
clinic
find
may
persist
month
year
follow
resolut
conjunct
lead
subject
visual
disturb
decreas
vision
photophobia
halo
develop
irregular
astigmat
due
chronic
visual
impact
treatment
includ
antiinflammatori
immunosuppress
agent
investig
treat
well
prevent
sei
though
often
end
resolv
without
scar
corneal
neovascular
research
demonstr
mild
corticosteroid
treatment
administ
topic
approxim
three
time
per
day
significantli
improv
ekc
symptom
use
short
term
acut
phase
diseas
lead
signific
ocular
side
effect
also
addit
benefit
use
topic
corticosteroid
acut
phase
infect
resolv
remain
persist
chronic
corticosteroid
treatment
proven
reduc
find
signific
challeng
mode
treatment
risk
complic
longterm
use
includ
glaucoma
cataract
addit
corticosteroid
treatment
sei
result
recurr
rate
consequenti
unsuccess
drug
discontinu
abruptli
viral
antigen
continu
attract
lymphocyt
caus
persist
excim
laser
ablat
help
studi
compar
topic
loteprednol
dexamethason
similar
outcom
sei
treatment
observ
signific
milder
topic
steroid
form
loteprednol
known
less
risk
advers
howev
import
note
shortterm
treatment
topic
steroid
limit
potenc
may
also
delay
viral
nonsteroid
antiinflammatori
drug
nsaid
anoth
altern
corticosteroid
approv
topic
ocular
use
exhibit
antiinflammatori
effect
without
substanti
risk
glaucoma
cataract
effect
seen
steroid
use
agent
work
arachidon
acid
pathway
inhibit
cyclooxygenas
subsequ
format
prostaglandin
thromboxan
prostacyclin
specif
ocular
use
shown
effect
case
allerg
conjunct
alkali
burn
herpet
uveiti
ocular
trauma
prepostop
cataract
refract
gordon
et
al
first
investig
nsaid
effect
adenovir
replic
specif
ketorolac
tromethamin
diclofenac
sodium
ophthalm
solut
earli
late
phase
infect
effect
nsaid
viral
titer
differ
control
group
affect
durat
viral
shed
contrast
prednisolon
treatment
shown
prolong
viral
pertain
subepitheli
infiltr
treatment
diclofenac
ketorolac
yield
statist
signific
reduct
compar
control
group
wherea
prednisolon
studi
suggest
nsaid
like
clinic
signific
antivir
import
note
even
though
nsaid
offer
higher
safeti
profil
longterm
use
comparison
topic
corticosteroid
seem
use
case
hadvassoci
conjunct
also
without
complic
associ
risk
corneal
pseudomembran
mark
fibrin
rich
exud
lack
blood
lymphat
vessel
true
membran
form
coalesc
exud
substantia
propria
mucou
membran
common
adenovir
keratoconjunct
may
hemorrhag
upon
histopatholog
studi
indic
presenc
fibrin
neutrophil
macrophag
effector
lymphocyt
activ
dendrit
cell
pseudomembran
format
present
sever
case
adenovir
keratoconjunct
set
intens
inflammatori
respons
figur
inoffic
remov
pseudomembran
could
benefici
prevent
complic
conjunctiv
fibrosi
longterm
sequela
addit
pseudomembran
manifest
along
sei
necessit
need
topic
antiinflammatori
manag
cyclosporin
nonsteroid
immunomodulatori
first
develop
novel
drug
inhibit
cell
specif
revers
first
use
whole
organ
transplant
attempt
avoid
transplant
reject
temper
host
immun
ocular
use
hadv
keratoconjunct
consid
need
dampen
immun
respons
corneal
complic
viru
especi
contraind
use
corticosteroid
limit
associ
corticosteroid
complic
topic
cyclosporin
concentr
altern
option
use
acut
phase
adenovir
keratoconjunct
success
reduc
risk
develop
corneal
find
well
chronic
treatment
persist
sei
case
resolv
cours
okumu
et
al
studi
efficaci
cyclosporin
allergan
irvin
california
usa
per
day
everi
day
treatment
sei
secondari
adenovir
epidem
keratoconjunct
case
persist
three
month
patient
studi
also
initi
treat
topic
corticosteroid
sever
month
regress
discontinu
due
subsequ
elev
iop
one
month
cyclosporin
treatment
eye
clear
sei
remain
decreas
number
system
ocular
side
effect
observ
case
studi
result
recurr
sei
discontinu
cyclosporin
like
effect
case
due
action
inhibit
cell
prolifer
activ
therebi
reduc
ocular
surfac
shown
efficaci
variou
ocular
diseas
vernal
keratoconjunct
ulcer
kerat
thygeson
superfici
punctat
kerat
herp
stromal
kerat
dri
eye
diseas
superior
limbic
keratoconjunct
mani
asena
et
al
also
evalu
treatment
option
acut
adenovir
keratoconjunct
use
either
topic
prednisolon
acet
conjunct
nonpreserv
artifici
tear
topic
cyclosporin
nonpreserv
artifici
tear
nonpreserv
artifici
tear
alon
comparison
artifici
tear
alon
corticosteroid
cyclosporin
group
exhibit
improv
symptom
well
shorter
durat
cyclosporin
prednisolon
group
also
similarli
effect
prevent
develop
sei
use
activ
phase
infect
suggest
possibl
prophylact
tacrolimu
anoth
immunosuppress
agent
also
demonstr
antiinflammatori
activ
like
cyclosporin
tacrolimu
initi
use
prevent
reject
organ
transplant
howev
despit
similar
effect
tacrolimu
cyclosporin
differ
chemic
makeup
cyclosporin
cyclic
endecapeptid
contrast
tacrolimu
macrocycl
lacton
calcineurin
inhibitor
enzym
necessari
cell
cyclosporin
tacrolimu
enter
cell
bind
respect
immunophilin
import
protein
interact
calcineurin
inhibit
action
block
calcineurin
subsequ
inhibit
transcript
sever
cytokin
necessari
immun
pathway
respons
particularli
cytokin
integr
mainten
differenti
surviv
cell
topic
tacrolimu
ophthalm
use
mainli
treatment
giant
papillari
conjunct
vernal
keratoconjunct
regard
effect
hadv
keratoconjunct
tacrolimu
effect
dexamethason
reduct
sei
subsequ
improv
vision
symptomolog
studi
signific
tacrolimu
superior
topic
corticosteroid
resolut
clinic
sign
symptom
also
offer
lower
recurr
rate
signific
rise
iop
sometim
seen
steroid
use
advers
effect
observ
patient
use
tacrolimu
manifest
burn
red
foreign
bodi
gener
sei
resist
taper
corticosteroid
tacrolimu
proven
effect
corticosteroidspar
anoth
promis
treatment
hadv
adopt
cell
therapi
involv
transfer
virusspecif
cell
tcelldeplet
patient
fight
infect
hadvspecif
cell
present
peripher
blood
healthi
individu
low
frequenc
result
donor
leukocyt
reportedli
use
patient
sever
hadv
infect
hadvspecif
cell
play
signific
role
viral
clearanc
adopt
transfer
hadvspecif
cell
would
immunotherapeut
agent
immens
benefit
patient
risk
dissemin
adenovir
infect
method
adopt
cell
therapi
involv
harvest
leukocyt
stimul
expand
vitro
use
peptidemhc
tetram
instead
use
lymphocyt
deriv
donor
transplant
yield
result
earli
two
therapi
along
antivir
use
appear
synergist
cardioton
steroid
digoxin
digitoxin
suggest
offer
new
strategi
target
suppress
hadv
histor
drug
use
treat
heart
failur
year
recent
also
shown
efficaci
cancer
treatment
treat
patient
demonstr
lesser
chanc
hartley
et
al
first
note
potenti
antivir
benefit
note
efficaci
hadv
due
drug
inhibit
nak
atpas
cell
surfac
lead
increas
intracellular
level
na
subsequ
ca
nak
atpas
import
cell
signal
molecul
bind
digoxin
digitoxin
initi
multipl
signal
cascad
influenc
gene
express
drug
also
alter
rna
splice
necessari
hadv
replic
preliminari
data
support
concentrationdepend
reduct
number
infect
cell
appar
damag
although
known
toxic
particularli
longterm
use
digoxin
antivir
use
cardioton
steroid
would
short
term
negat
associ
system
complic
drug
seem
efficaci
hadv
serotyp
ad
serv
potenti
treatment
therapi
treatment
prophylaxi
thu
repurpos
cardioton
steroid
antivir
agent
shortterm
treatment
adenovir
keratoconjunct
well
prophylact
use
individu
close
contact
patient
epidem
furthermor
marrugallorenzo
et
al
report
mifepriston
synthet
steroid
drug
possess
antiadenovir
properti
via
interfer
viral
entri
nucleu
could
repurpos
treat
adenovir
potenti
benefit
pvi
well
topic
immunosuppress
therapi
gave
rise
develop
combin
pvisteroid
ophthalm
solut
idea
combin
element
employ
antisept
properti
pvi
conjunct
symptomat
relief
inflamm
ad
benefit
reduc
risk
andor
treatment
sei
format
initi
efficaci
combo
pvi
dexamethason
dose
qid
five
day
evalu
small
studi
nine
eye
util
rapid
pathogen
screen
adeno
detectorposit
acut
viral
pilot
studi
includ
clinic
conjunctiv
inject
discharg
serolog
reduct
quantit
polymeras
chain
reaction
titer
erad
infecti
viru
determin
cell
cultur
confirmatori
immunofluoresc
combin
treatment
dose
qid
seven
day
also
shown
improv
clinic
score
scleral
inflamm
ocular
neovascular
eyelid
inflamm
friabil
vasculatur
inflammatori
discharg
epiphora
compar
treatment
cidofovir
tobramycindexamethason
ophthalm
suspens
balanc
salt
solut
rabbit
moreov
pvidexamethason
combin
proven
effect
reduc
viral
titer
delay
viral
compar
pvidexamethason
combin
treatment
dexamethason
alon
combin
drop
increas
recoveri
also
reduc
risk
develop
sei
effect
steroid
well
document
sole
topic
corticosteroid
therapi
risk
increas
viral
replic
prolong
shed
delay
resolut
activ
infect
signific
treatment
challeng
allevi
addit
addit
mention
treatment
benefit
combin
pvidexamethason
ophthalm
formul
display
favor
safeti
profil
well
toler
administ
also
statist
signific
effect
intraocular
pressur
often
associ
topic
corticosteroid
use
report
side
effect
limit
increas
sting
upon
instil
compar
treatment
palli
artifici
surgic
manag
usual
requir
adenovir
keratoconjunct
howev
may
necessari
case
signific
fibrot
remodel
conjunctiva
sustain
corneal
scar
visual
consequ
membran
develop
mucos
surfac
differenti
pseudomembran
true
membran
latter
clinic
distinguish
induc
bleed
upon
persist
pseudomembran
lead
subepitheli
fibrosi
conjunctiv
mucosa
symblepharon
format
punctal
thu
rare
case
may
requir
repair
fornix
associ
lid
anatomi
defect
entropion
ectropion
furthermor
streptococc
coinfect
may
present
sever
case
membran
precipit
corneal
perfor
necessit
patient
chronic
adenovir
corneal
opacif
follow
resolut
acut
infect
phototherapeut
keratectomi
ptk
altern
option
corneal
surgeri
transplant
corneal
transpar
compromis
corneal
irregular
may
result
sequela
immun
respons
pathogen
fortuit
scar
often
superfici
natur
virtu
affect
subepitheli
layer
transepitheli
ptk
low
dose
mitomycin
c
shown
benefit
case
report
improv
photophobia
best
correct
vision
contrast
furthermor
decreas
coma
secondari
astigmat
total
higherord
aberr
note
ptk
sei
adenovir
though
mani
consid
adenovir
conjunct
diseas
selflimit
econom
burden
affect
individu
high
contagion
risk
potenti
longterm
visual
complic
requir
treatment
protocol
studi
indic
inflammatori
process
affect
cornea
begin
prodrom
period
adenovir
infect
thu
question
theori
selflimit
ad
potenti
factor
immedi
therapeut
dissemin
hadv
also
signific
health
burden
particularli
individu
factor
put
great
risk
morbid
mortal
adenovir
infect
individu
includ
children
elderli
immunocompromis
individu
patient
acut
graft
versu
host
diseas
immunosuppress
fdaapprov
drug
treat
hadv
infect
eye
care
provid
use
multipl
pharmaceut
offlabel
manag
hadv
ocular
infect
final
propens
latent
hadv
becom
reactiv
easili
transmiss
warrant
need
addit
research
develop
effect
prophylact
antivir
drug
new
treatment
consider
includ
sialic
acid
analog
cold
atmospher
plasma
cap
nchlorotaurin
even
benzalkonium
chlorid
bak
sialic
acid
play
role
initi
attach
fiber
knob
adenovir
virion
facilit
sialic
acid
analog
theoriz
block
sialic
acidcontain
glycan
act
cellular
receptor
topic
cap
use
dermatolog
diseas
chronic
wound
demonstr
adenovir
typedepend
antivir
effect
may
nchlorotaurin
endogen
antimicrobi
agent
shown
shorten
durat
ill
well
toler
vitro
vivo
experi
howev
phase
ii
clinic
trial
prematur
end
due
inabl
meet
primari
secondari
endpoint
includ
clear
bulbar
conjunctiva
erad
viru
tear
film
fellow
eye
involv
reduct
sei
clear
bak
commonli
found
preserv
ophthalm
formul
typic
present
concentr
studi
prove
effect
bak
antivir
agent
adenoviru
concentr
higher
howev
note
disadvantag
ocular
toxic
known
futur
consider
manag
adenovir
keratoconjunct
requir
consider
antisepsi
mitig
sequela
host
inflammatori
respons
furthermor
special
consider
persist
latent
hadv
subtyp
immunocompromis
individu
requir
identif
exact
mechan
underli
adapt
immun
respons
adenovir
infect
prudent
develop
novel
therapeut
sourc
howev
lack
anim
model
accur
mimic
complex
human
ocular
anatomi
also
illustr
proper
replic
infect
human
adenovirus
prove
deceler
new
tabl
highlight
efficaci
advers
effect
antivir
antiinflammatori
agent
discuss
summari
sever
challeng
regard
treatment
adenovir
keratoconjunct
though
solut
issu
research
requir
determin
standard
protocol
tabl
